Abstract:Background: Numerous reports have shown that a combination of two or more drugs leads to better cancer treatment. Inhibitors of zeste homology 2 and epidermal growth factor receptor have been widely used in cancer treatments. However, the mechanisms of the combined use of these two drugs remain elusive. Methods: Sul forhodamine B assays and Alexa Fluor (R)-488 Annexin V/Dead Cell Apoptosis Kit were used to detect the cell proliferation and cell apoptosis in vitro, respectively. Western blotting analysis was used to detect the relative protein expression, and xenografted tumor was generated in nude mice to evaluate the effect in vivo. Results: Treatment with either Gefitinib ranging from 0 to 12.5 mu M or GSK126 ranging from 0 to 8.3 mu M caused adore-dependent decrease in the cell survival fraction, and the combination of Gefitinib at 12.5 mu M and GSK126 at 8.3 mu M caused further significant decrease. The combination indexes were 0.061, 0.591, 0.713, and 0.371 for MGC803, A549, PC-3, and MDB-MA-231, respectively. In MGC803 cells, the combination of GSK126 and Gefitinib synergistically induced cell apoptosis (56.2%), which was markedly higher as compared to either drug alone (7.6% and 10.6%, P<0.05). Treatment with either Gefitinib or GSK126 alone induced a significant increase in cell apoptosis in LC3-II and p-ULK, whereas the combination of the two induced a further increase. Pretreatment with an autophagy inhibitor, 3-methyladenine, prevented the apoptosis induced by the combined use of Gefitinib and GSK126. In addition, the combined use of Gefitinib and GSK126 also inhibited the activation of mammalian target of rapamycin signaling pathway. Furthermore, the combined use of GSK126 and Gefitinib synergistically inhibited xenografted tumor proliferation. Conclusion: The combined use of GSK126 and Gefitinib exerts a synergic effect on tumor growth inhibition both in vitro and in vivo through inducing autophagy and promoting apoptosis. Therefore, GSK126 and Gefitinib in combination may be considered as a potential strategy in treating solid tumor clinically.

The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer

ATR inhibition is a promising radiosensitizing strategy for triple negative breast cancer.

Data from ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer

Inhibition of Aurora A Promotes Chemosensitivity Via Inducing Cell Cycle Arrest and Apoptosis in Cervical Cancer Cells.

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Effect of Aurora Inhibitor VX-680 on Proliferation and Apoptosis of CML Cells

BIRB796, the Inhibitor of P38 Mitogen-Activated Protein Kinase, Enhances the Efficacy of Chemotherapeutic Agents in ABCB1 Overexpression Cells.

Inhibition of Aurora-A Results in Increased Cell Death in 3-Dimensional Culture Microenvironment, Reduced Migration and is Associated with Enhanced Radiosensitivity in Human Nasopharyngeal Carcinoma

Inhibition of the P38 Mapk Pathway Sensitizes Human Gastric Cells to Doxorubicin Treatment in Vitro and in Vivo

Inhibition of p38-MK2 pathway enhances the efficacy of microtubule inhibitors in breast cancer cells

VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma.

Effect of Aurora A inhibitor VX-680 on chemosensitivity in human cervical cancer cell

Cyclovirobuxine D Exerts Anticancer Effects by Suppressing the EGFR-FAK-AKT/ERK1/2-Slug Signaling Pathway in Human Hepatocellular Carcinoma

BIRB796, an Inhibitor of p38 Mitogen-Activated Protein Kinase, Inhibits Proliferation and Invasion in Glioblastoma Cells

C118P Exerted Potent Anti-Tumor Effects Against Melanoma with Induction of G2/M Arrest Via Inhibiting the Expression of BUB1B.

Combined CB2 receptor agonist and photodynamic therapy synergistically inhibit tumor growth in triple negative breast cancer

Dual-target MDM2/MDMX Inhibitor Increases the Sensitization of Doxorubicin and Inhibits Migration and Invasion Abilities of Triple-Negative Breast Cancer Cells Through Activation of TAB1/TAK1/p38 MAPK Pathway.

Angiogenesis Inhibition and Cell Cycle Arrest Induced by Treatment with Pseudolarix Acid B Alone or Combined with 5-Fluorouracil

Pharmacological Inhibition Of P38 Mapk By Sb203580 Increases Resistance To Carboplatin In A2780cp Cells And Promotes Growth In Primary Ovarian Cancer Cells

Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells.

Inhibition of MYC Suppresses Programmed Cell Death Ligand-1 Expression and Enhances Immunotherapy in Triple-Negative Breast Cancer